Reliable carbon-free power for the world — michelle catts, senior vice president, nuclear programs, ge-hitachi nuclear energy.

Michelle Catts is the Senior Vice President of Nuclear Programs at GE-Hitachi (GEH — https://nuclear.gepower.com/) located in Wilmington, NC.

Ms. Catts has over 18 years of demonstrated managerial and technical expertise in nuclear Regulatory Affairs and currently is responsible for ensuring world-class Quality, Continuous Improvement, Regulatory Affairs, and oversight of Environment, Health & Safety programs. She manages a multimillion-dollar budget and over a 30-member organization. She provides licensing and quality leadership and guidance to support nuclear fuel facility licensing, current nuclear fleet fuel reload/outage licensing activities, new reactor and new fuel opportunities, Technical Regulations and Standards, and GE-Hitachis’s Vallecitos and Morris sites.

Prior to joining GE-Hitachi, Ms. Catts worked for the U.S. Nuclear Regulatory Commission (NRC) where she held positions of increasing responsibility including as a nuclear reactor inspector stationed onsite at nuclear power plants up to the Policy Advisor to the Presidential Appointed NRC Chairman.

Ms. Catts holds a B.S. in Nuclear Engineering from North Carolina State University and is currently working on her MBA at UNCW.

Ms. Catts is also on the board of Smart Start of New Hanover County, an organization that seeks to build bridges to develop, sustain and enhance health, family support and early education services for all children, ages birth to five.

Regeneration, Resuscitation & Biothreat Countermeasures — Commander Dr. Jean-Paul Chretien, MD, Ph.D., Program Manager, Biological Technology Office, DARPA

Commander Dr. Jean-Paul Chretien, MD, Ph.D. (https://www.darpa.mil/staff/cdr-jean-paul-chretien) is a Program Manager in the Biological Technology Office at DARPA, where his research interests include disease and injury prevention, operational medicine, and biothreat countermeasures. He is also responsible for running the DARPA Triage Challenge (https://triagechallenge.darpa.mil/).

Prior to coming to DARPA, CDR Dr. Chretien led the Pandemic Warning Team at the Defense Intelligence Agency’s National Center for Medical Intelligence, and as a naval medical officer, his previous assignments include senior policy advisor for biodefense in the White House Office of Science and Technology Policy; team lead for Innovation & Evaluation at the Armed Forces Health Surveillance Branch; and director of force health protection for U.S. and NATO forces in southwestern Afghanistan.

A proud mentor to nine graduate students and Oak Ridge Institute for Science and Education (ORISE) fellows, CDR Dr. Chretien received the Rising Star Award from the American College of Preventive Medicine, Best Publication of the Year Award from the International Society for Disease Surveillance, and Skelton Award for Public Service from the Harry S. Truman Scholarship Foundation. He has published over 50 peer-reviewed journal articles and 10 book chapters.

CDR Dr. Chretien earned a Bachelor of Science degree in political science from the United States Naval Academy, Master of Health Science in biostatistics and Doctor of Philosophy in genetic epidemiology degrees from the Johns Hopkins Bloomberg School of Public Health, and a Doctor of Medicine degree from the Johns Hopkins University School of Medicine. He completed his residency in general preventive medicine at the Walter Reed Army Institute of Research and fellowship in health sciences informatics at the Johns Hopkins University School of Medicine.

Dedicated to ending the HIV epidemic — dr. moupali das, MD, MPH, executive director, HIV clinical research, gilead sciences.

Dr. Moupali Das, MD, MPH, is Executive Director, HIV Clinical Research, in the Virology Therapeutic Area, at Gilead Sciences (https://www.gilead.com/), where she leads the pre-exposure prophylaxis (PrEP) clinical drug development program, including evaluating the safety and efficacy of a long-acting, twice yearly, subcutaneous injection being studied for HIV prevention. Her responsibilities also include expanding the populations who may benefit from PrEP.

Dr. Das has led high-performing teams in academic medicine, public health, implementation science, and cross-functionally in drug development. She has successfully helped develop, implement, and evaluate how to better test, link to care, increase virologic suppression, and improve quality of life for people with HIV, and to prevent HIV in those who may benefit from PrEP.

During the COVID19 pandemic, Dr. Das assisted her colleagues in the COVID-19 treatment program, leading the evaluation of a COVID-19 treatment for use in pregnant women and children from the compassionate use program.

After completing her undergraduate degree in Biochemical Sciences at Harvard College, medical school and internal medicine residency training at Columbia University and New York Presbyterian Hospital, Dr. Das came to University of California, San Francisco (UCSF) for fellowship training in Infectious Diseases and to University of California, Berkeley for her MPH in Epidemiology. She cared for HIV patients at San Francisco General’s storied Ward 86 clinic and attended on the inpatient ID Consult Service. She is recognized internally and externally for her expertise in epidemiology, public health, advocacy, and community engagement.

Prior to joining Gilead, Dr. Das developed a novel population-based indicator, community viral load (CVL), to evaluate the impact of treatment as prevention. Her CVL research was the basis for using viral suppression to evaluate the effectiveness of President Barack Obama’s National HIV/AIDS Strategy. She also served on the Institute of Medicine Committee on Data Systems for Monitoring HIV/AIDS care.

Dr. Das has authored over 60 manuscripts, presented at scientific conferences, policy forums, and for community and advocacy organizations. Her publications have been highly cited and garnered significant press coverage including in The New York Times and Nature.

Dr. Das appears in her personal capacity and any views expressed are her own.

Blake Lemoine, the Google engineer fired for violating the company’s confidentiality policy, has now expressed concerns about the risks associated with AI-driven chatbots like Microsoft’s Bing AI.

The latest AI models, according to him, are the most potent technological advancement since the atomic bomb and can alter the course of history fundamentally.

As the ChatGPT and Whisper APIs launch this morning, OpenAI is changing the terms of its API developer policy, aiming to address developer — and user — criticism.

Starting today, OpenAI says that it won’t use any data submitted through its API for “service improvements,” including AI model training, unless a customer or organization opts in. In addition, the company is implementing a 30-day data retention policy for API users with options for stricter retention “depending on user needs,” and simplifying its terms and data ownership to make it clear that users own the input and output of the models.

Greg Brockman, the president and chairman of OpenAI, asserts that some of these changes aren’t changes necessarily — it’s always been the case that OpenAI API users own input and output data, whether text, images or otherwise. But the emerging legal challenges around generative AI and customer feedback prompted a rewriting of the terms of service, he says.

Advancing Biomedical R&D & Clinical Development In Saudi Arabia — Dr. Abdelali Haoudi, Ph.D., Managing Director, Biotechnology Park, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs.

Dr. Abdelali Haoudi, Ph.D. (https://kaimrc-biotech.org.sa/dr-abdelali-haoudi/) currently leads Strategy and Business Development functions, and is also Managing Director of the Biotechnology Park, at King Abdullah International Medical Research Center, at the Ministry of National Guard Health Affairs. He is also Distinguished Scholar at Harvard University-Boston Children’s Hospital.

Dr. Haoudi is an international Research & Development and Innovation Executive with over 25 years experience, having held several senior positions in Research and Development and Innovation. He has vast experience in science and technology policy development, strategy and business development, corporate development and international partnerships development.

Dr. Haoudi has held several senior and prestigious positions in the academia, government and private sectors globally, including North America, North Africa, Europe and Middle East. Some of the key positions include Founding Vice President for Research, Executive Director for Biomedical Research Institute, and Chairman, at the National Research Fund at Qatar Foundation.

Dr. Haoudi was also Research Professor of cancer and infectious diseases at the University of Virginia and Eastern Virginia Medical School and a fellow of the US National Institutes of Health (NIH). He has held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institute Pasteur (France).

Dr. Haoudi is an elected member of Hassan II Academy for Science and Technology since 2006. He graduated from University Paris XI and Paris VI, France in 1996 with a doctoral degree in cellular and molecular genetics.

Dr. Haoudi received executive education from Harvard Business School in Corporate Management and Strategy and received multiple awards including Fogarty International Award. He has published numerous peer-reviewed international research publications and served as Founding Editor-In-Chief for the Journal of Biomedicine and Biotechnology.

Climate change policy has entered a new era. The growing row between the United States and the European Union over the impacts of the new American green subsidy regime makes that all too clear. Yet, in many ways, this story is ultimately about China.

For the last 20 years, developed countries have used three main types of policies to cut their greenhouse gas emissions. Renewable energy mandates have required electricity generators to invest in solar, wind, hydro, and geothermal power. Emissions trading schemes for energy and industrial businesses put a price on carbon. And energy efficiency standards have been progressively improved on a whole range of products, from vehicles and white goods to homes.

This is NOT for ChatGPT, but instead its the AI tech used in beating GO, Chess, DOTA, etc. In other words, not just generating the next best word based on reading billions of sentences, but planning out actions to beat real game opponents (and winning.) And it’s free.

Reinforcement learning is an area of machine learning that involves taking right action to maximize reward in a particular situation. In this full tutorial course, you will get a solid foundation in reinforcement learning core topics.

The course covers Q learning, SARSA, double Q learning, deep Q learning, and policy gradient methods. These algorithms are employed in a number of environments from the open AI gym, including space invaders, breakout, and others. The deep learning portion uses Tensorflow and PyTorch.

The course begins with more modern algorithms, such as deep q learning and policy gradient methods, and demonstrates the power of reinforcement learning.

Then the course teaches some of the fundamental concepts that power all reinforcement learning algorithms. These are illustrated by coding up some algorithms that predate deep learning, but are still foundational to the cutting edge. These are studied in some of the more traditional environments from the OpenAI gym, like the cart pole problem.

Code: https://github.com/philtabor/Youtube-Code-Repository/tree/ma…ntLearning.

Course Contents
(00:00:00) Intro.
(00:01:30) Intro to Deep Q Learning.
(00:08:56) How to Code Deep Q Learning in Tensorflow.
(00:52:03) Deep Q Learning with Pytorch Part 1: The Q Network.
(01:06:21) Deep Q Learning with Pytorch part 2: Coding the Agent.
(01:28:54) Deep Q Learning with Pytorch part.
(01:46:39) Intro to Policy Gradients 3: Coding the main loop.
(01:55:01) How to Beat Lunar Lander with Policy Gradients.
(02:21:32) How to Beat Space Invaders with Policy Gradients.
(02:34:41) How to Create Your Own Reinforcement Learning Environment Part 1
(02:55:39) How to Create Your Own Reinforcement Learning Environment Part 2
(03:08:20) Fundamentals of Reinforcement Learning.
(03:17:09) Markov Decision Processes.
(03:23:02) The Explore Exploit Dilemma.
(03:29:19) Reinforcement Learning in the Open AI Gym: SARSA
(03:39:56) Reinforcement Learning in the Open AI Gym: Double Q Learning.
(03:54:07) Conclusion.

Course from Machine Learning with Phil. Check out his YouTube channel: https://www.youtube.com/channel/UC58v9cLitc8VaCjrcKyAbrw.

A fully-connected annealer extendable to a multi-chip system and featuring a multi-policy mechanism has been designed by Tokyo Tech researchers to solve a broad class of combinatorial optimization (CO) problems relevant to real-world scenarios quickly and efficiently. Named Amorphica, the annealer has the ability to fine-tune parameters according to a specific target CO problem and has potential applications in logistics, finance, machine learning, and so on.

The modern world has grown accustomed to an efficient delivery of goods right at our doorsteps. But did you know that realizing such an efficiency requires solving a mathematical problem, namely what is the best possible route between all the destinations? Known as the “traveling salesman problem,” this belongs to a class of mathematical problems known as “combinatorial optimization” (CO) problems.

As the number of destinations increases, the number of possible routes grows exponentially, and a brute force method based on exhaustive search for the best route becomes impractical. Instead, an approach called “annealing computation” is adopted to find the best route quickly without an exhaustive search.

Also weighing in with an online essay was the Rev. Russell Moore, formerly head of the Southern Baptist Convention’s public policy division and now editor-in-chief of the evangelical magazine Christianity Today. He confided to his readers that his first sermon, delivered at age 12, was a well-intentioned mess.

“Preaching needs someone who knows the text and can convey that to the people — but it’s not just about transmitting information,” Moore wrote. “When we listen to the Word preached, we are hearing not just a word about God but a word from God.”

“Such life-altering news needs to be delivered by a human, in person,” he added. “A chatbot can research. A chatbot can write. Perhaps a chatbot can even orate. But a chatbot can’t preach.”